Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Barry_Greene
|
| gptkbp:collaboratesWith |
gptkb:Biogen
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
central nervous system disorders
|
| gptkbp:foundedYear |
2010
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ:SAGE
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US78667J1088
|
| gptkbp:marketCap |
mid-cap
|
| gptkbp:name |
gptkb:Sage_Therapeutics,_Inc.
|
| gptkbp:numberOfEmployees |
~400
|
| gptkbp:product |
gptkb:Zulresso
gptkb:Zuranolone |
| gptkbp:regulates |
FDA approval for Zulresso
|
| gptkbp:stockExchange |
gptkb:NASDAQ
gptkb:stock_market_index |
| gptkbp:stockSymbol |
gptkb:SAGE
|
| gptkbp:therapeuticArea |
gptkb:depression
neurology psychiatry |
| gptkbp:tradedOn |
gptkb:NASDAQ:SAGE
|
| gptkbp:website |
https://www.sagerx.com/
|
| gptkbp:bfsParent |
gptkb:Sage_Therapeutics
|
| gptkbp:bfsLayer |
5
|